樂觀
$155.14
情境價格
$136.290
-0.286 (-0.21%)收盤時
Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, and vascular access. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of the MANTA Vascular Closure device, Arrow OnControl powered bone biopsy system, GuideLiner, Turnpike and TrapLiner catheters.
Teleflex Inc is a good buy right now due to its current price of $136.29, which is below the analyst price target of $158, indicating a potential upside of 15.9%. Additionally, the stock has shown a strong 20-day change of +11.65%, suggesting positive momentum. However, the main risk is the high debt to equity ratio of 96.68%, indicating potential financial leverage concerns.
BofA
$158
2026-09-28
BofA
2026-09-28
目標價
$158
UBS
$158
2026-08-11
UBS
2026-08-11
目標價
$158
Truist
$150
2026-08-10
Truist
2026-08-10
目標價
$150
Raymond James
$155
2026-08-07
Raymond James
2026-08-07
目標價
$155
Needham
$159
2026-07-31
Needham
2026-07-31
目標價
$159
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Teleflex Receives FDA Breakthrough Device Designation for Freesolve™ RMS

Teleflex to Host Q3 Financial Results Conference Call on November 5, 2026

Teleflex Completes Patient Enrollment in BIOMAG™-LL Clinical Study

Key Wall Street Calls on Monday

Teleflex Appoints New Board Member Sean M. Salmon
Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, and vascular access. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of the MANTA Vascular Closure device, Arrow OnControl powered bone biopsy system, GuideLiner, Turnpike and TrapLiner catheters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Teleflex Inc is a good buy right now due to its current price of $136.29, which is below the analyst price target of $158, indicating a potential upside of 15.9%. Additionally, the stock has shown a strong 20-day change of +11.65%, suggesting positive momentum. However, the main risk is the high debt to equity ratio of 96.68%, indicating potential financial leverage concerns.
12 analysts cover TFX: 10 rate it Buy, 2 Hold and 0 Sell. The average price target is 136.20.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。